Sanofi's Acomplia drug approved in Brazil
Thu Apr 26, 2007 2:01AM EDT
French drugmaker Sanofi-Aventis said on Thursday that its anti-obesity Acomplia drug had received approval from Brazil's health authority.

Sanofi hopes Acomplia can help offset future lost sales to generics.

Acomplia has been approved in the European Union, but reimbursements remain limited and the drug is still awaiting approval from U.S. health authorities following several delays. Sanofi has in the past forecast $3 billion in annual sales from Acomplia.

Weight loss concern has a caught up fire with the young and the old in the recent times. But how many of actually adopt effectual methods to attain weight loss? Practices like strenuous exercises and starving diets do help some, but that may not work for all.

In view of the weight loss craze, many weight loss medications are now marketed. Amongst these Acomplia (Zimulti in the USA) has emerged as a promising weight loss drug, with its long trail of success stories. Nigel Wescott, spokesperson of Acomplia Buy comments, “Despite the tough competition in the weight loss market, Acomplia has proven to be a medication which has effectually helped many obese and overweight individuals shed weight”.

Mr. Wescott says, “Many pharmaceuticals have preparing to launch competitors of Acomplia soon, but their fate is yet uncertain”. Pfizer and Merck, the other well-known drug makers are preparing to give a tough competition to the Sanofi-Aventis’s Acomplia. Taranabant and CP-945598 are weight loss medications which work on the CB-1 receptors, regulating appetite of the body.

Acomplia Buy is a dependable multi-lingual informative website. Information on weight loss medications such as Acomplia, Xenical and Reductil are made available at Acomplia Buy. Useful information such as Acomplia approval FDA, Acomplia Sanofi- Aventis, Rimonabant RIO, Acomplia pill benefits, Acomplia side effects are also made accessible at Acomplia Buy, which is beneficial to widen your range of understanding. Latest articles and latest news on weight loss medications are some of the other useful information made accessible at Acomplia Buy.

Source: AcompliaBuy.com

People who are 100 pounds or more overweight are the fastest-growing group of overweight people in the United States, researchers reported on Monday.

They found the proportion of the severely obese was 50 percent higher in 2005 than it had been in 2000 — a startling rate of growth.

“The proportion of people at the high end of the weight scale continues to increase at a brisk rate despite increased public attention on the risks of obesity and the increased use of drastic weight loss strategies such as bariatric surgery,” said Roland Sturm, an economist at Rand Corporation, a nonprofit research institute.

“The explosion in the use of bariatric (weight-loss) surgery has made no noticeable dent in the trend of morbid obesity,” Sturm added in a statement.

The researchers found that based on self-reported height and weight, which tends to underestimate the weight part, 3 percent of Americans are already severely obese — defined as having a body mass index of 40 or higher.

Body mass index is calculated by dividing weight in kilograms by the square of a person’s height in meters.

The researchers, whose report will be published later this year in the Journal of Public Health, found that the proportion of Americans with a BMI of 30 or more increased by 24 percent between 2000 and 2005.

Source: Reuters

Acomplia (rimonabant) has not yet become a licensed product for smoking cessation in the UK. Whilst during clinical studies the drug clearly demonstrated a reduced craving for nicotine in patients the drug has only at the moment been approved as an obesity treatment. As this is a prescription medication we strongly advise that you seek to have a face-to-face consultation with your doctor in the first instance. This information should not be considered as a replacement to a doctor’s treatment.

http://globalonlinepharmacy.tripod.com/

Sanofi-Aventis said that Switzerland''s regulatory body Swissmedic has approved anti-obesity drug Acomplia for sale in the country.


Sanofi-Aventis said the regulator has authorised the use of the drug for "for obese patients (Body Mass Index - BMI - greater than or equal to 30 kg/m2) or for overweight patients (BMI greater than or equal to 27 kg/m2) with at least one associated cardiovascular risk factor, after insufficient weight reduction following physical activity or alimentary adaptation.



Physicians in Switzerland may prescribe the 20 mg once-daily acomplia pill along with a light diet and physical activity for obese or overweight patients with at least one associated cardiovascular risk factor and after insufficient weight reduction following physical activity or food adaptation.